Anavex Life Sciences Corp. NMS · AVXL
Price alert —
Sign in to get a one-time email the moment AVXL crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · AVXL
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2025-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-09-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-06-30 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2025-03-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
| 2024-12-31 | — | $-0.0B | $-0.0B | $-0.0B | — | — |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare AVXL vs peers
Line AVXL up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
Add tickers to compare with AVXL
~30 metrics across Snapshot, OdysseyHQ zone, Valuation, Growth, Quality, Technicals, Sentiment, and Risk — with a weighted score and a one-line read on each.
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-02-09 | -0.06 | -0.11 | +45.5% | -9.0% |
| 2025-11-25 | -0.11 | -0.15 | +26.7% | +11.6% |
| 2025-08-12 | -0.16 | -0.14 | -10.3% | -2.0% |
| 2025-05-13 | -0.13 | -0.15 | +13.3% | +0.6% |
| 2025-02-12 | -0.14 | -0.17 | +17.6% | -2.6% |
| 2024-12-23 | -0.14 | -0.17 | +17.6% | -2.8% |
| 2024-08-06 | -0.14 | -0.18 | +22.2% | -10.8% |
| 2024-05-09 | -0.13 | -0.13 | — | -1.8% |
| 2024-02-07 | -0.11 | -0.15 | +26.7% | +1.8% |
| 2023-11-27 | -0.12 | -0.15 | +20.0% | +6.6% |
| 2023-08-08 | -0.14 | -0.17 | +17.6% | +16.7% |
| 2023-05-09 | -0.17 | -0.18 | +5.6% | +3.2% |
| 2023-02-07 | -0.17 | -0.20 | +15.0% | -7.0% |
| 2022-11-28 | -0.18 | -0.16 | -9.1% | -1.8% |
| 2022-08-09 | -0.16 | -0.16 | +2.0% | +8.1% |
| 2022-05-10 | -0.14 | -0.17 | +17.6% | -4.9% |
| 2022-02-09 | -0.14 | -0.16 | +12.5% | +7.7% |
| 2021-11-24 | -0.15 | -0.14 | -4.7% | +2.4% |
| 2021-08-12 | -0.14 | -0.14 | — | +1.4% |
| 2021-05-13 | -0.12 | -0.15 | +20.0% | — |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| AVXL ★ | $0B | — | -4.6 | — | — | 1.8 | — | — | — | -9.37% |
| LLY | $1,055B | 42.0 | 26.4 | — | 29.7 | 33.9 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $384B | 31.8 | 18.8 | 0.9 | 17.9 | 3.7 | 19.5% | 0.4% | 61.5% | 5.93% |
| JNJ | $621B | 30.0 | 20.1 | 6.3 | 18.6 | 7.6 | 68.1% | 6.6% | -1.0% | — |
| MRK | $322B | 36.5 | 13.5 | — | 12.1 | 7.0 | 76.7% | 4.9% | — | 4.36% |
| ABBV | $454B | 125.3 | 15.8 | 7.2 | 17.1 | -68.2 | 72.0% | 12.4% | -46.2% | 4.59% |
| PFE | $142B | 19.1 | 8.8 | — | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.69% |
| TMO | $215B | 31.8 | 21.2 | — | 20.9 | 4.1 | 40.9% | 6.2% | 11.3% | 2.57% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 27.84%
| Holder | Shares | % out |
|---|---|---|
| Blackrock Inc. | 7,609,618 | 8.21% |
| State Street Corporation | 4,512,028 | 4.87% |
| Vanguard Capital Management LLC | 3,863,950 | 4.17% |
| Two Sigma Investments, LP | 3,247,888 | 3.50% |
| Geode Capital Management, LLC | 2,188,275 | 2.36% |
| Susquehanna International Group, LLP | 995,663 | 1.07% |
| Summit Financial, LLC | 940,455 | 1.01% |
| Bank of America Corporation | 863,150 | 0.93% |
| Goldman Sachs Group Inc | 804,435 | 0.87% |
| Vanguard Portfolio Management LLC | 783,148 | 0.85% |
Insider activity · 90d
No insider trades for AVXL in last 90d.
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-20 | FORM 8-K | view · |
| 8-K | 2026-06-26 | FORM 8-K | view · |
| 8-K | 2026-05-22 | FORM 8-K | view · |
| 8-K | 2026-05-15 | FORM 8-K | view · |
| 8-K | 2026-05-06 | FORM 8-K | view · |
| 8-K | 2026-03-25 | FORM 8-K | view · |
| 8-K | 2026-02-25 | FORM 8-K | view · |
| 10-Q | 2026-02-09 | FORM 10-Q | view · |
| 8-K | 2026-02-09 | FORM 8-K | view · |
| 4 | 2026-01-09 | Insider transaction (Form 4) | view · |
| 4 | 2026-01-09 | Insider transaction (Form 4) | view · |
| 10-K | 2025-11-25 | FORM 10-K | view · |
| 8-K | 2025-11-25 | FORM 8-K | view · |
| 8-K | 2025-11-14 | FORM 8-K | view · |
| 4 | 2025-10-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-10-03 | Insider transaction (Form 4) | view · |
| 4 | 2025-09-12 | Insider transaction (Form 4) | view · |
| 4 | 2025-08-22 | Insider transaction (Form 4) | view · |
| 4 | 2025-08-22 | Insider transaction (Form 4) | view · |
| 10-Q | 2025-08-12 | FORM 10-Q | view · |
| 8-K | 2025-07-28 | FORM 8-K | view · |
| 8-K | 2025-07-03 | FORM 8-K | view · |
| 8-K | 2025-06-13 | FORM 8-K | view · |
| 4 | 2025-06-09 | Insider transaction (Form 4) | view · |
| 10-Q | 2025-05-13 | FORM 10-Q | view · |
| 4 | 2025-04-30 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-30 | Insider transaction (Form 4) | view · |
| DEF 14A | 2025-04-25 | FORM DEF 14A | view · |
| 4 | 2025-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2025-04-02 | Insider transaction (Form 4) | view · |
| 4 | 2025-03-26 | Insider transaction (Form 4) | view · |
| 10-Q | 2025-02-12 | FORM 10-Q | view · |
| 4 | 2025-01-17 | Insider transaction (Form 4) | view · |
| 4 | 2025-01-17 | Insider transaction (Form 4) | view · |
| 4 | 2024-12-23 | Insider transaction (Form 4) | view · |
| 4 | 2024-12-23 | Insider transaction (Form 4) | view · |
| 10-K | 2024-12-23 | FORM 10-K | view · |
| 4 | 2024-12-06 | Insider transaction (Form 4) | view · |
| 4 | 2024-12-06 | Insider transaction (Form 4) | view · |
| 10-Q | 2024-08-06 | FORM 10-Q | view · |
| 8-K | 2024-07-30 | FORM 8-K | view · |
| 8-K | 2024-06-21 | FORM 8-K | view · |
| 4 | 2024-06-17 | Insider transaction (Form 4) | view · |
| 4 | 2024-05-17 | Insider transaction (Form 4) | view · |
| 10-Q | 2024-05-09 | FORM 10-Q | view · |
| 8-K | 2024-05-09 | FORM 8-K | view · |
| DEF 14A | 2024-05-06 | FORM DEF 14A | view · |
| 4 | 2024-04-01 | Insider transaction (Form 4) | view · |
| 4 | 2024-02-23 | Insider transaction (Form 4) | view · |
| 4 | 2024-02-23 | Insider transaction (Form 4) | view · |
| 4 | 2024-02-23 | Insider transaction (Form 4) | view · |
| 4 | 2024-02-23 | Insider transaction (Form 4) | view · |
| 4 | 2024-02-23 | Insider transaction (Form 4) | view · |
| 10-Q | 2024-02-07 | FORM 10-Q | view · |
| 4 | 2024-01-12 | Insider transaction (Form 4) | view · |
| 4 | 2024-01-12 | Insider transaction (Form 4) | view · |
| 10-K | 2023-11-27 | FORM 10-K | view · |
About AVXL
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Its ANAVEX 2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. The ANAVEX 2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The company's ANAVEX 3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a clinical stage drug candidate demonstrating disease-modifying activity against Alzheimer's disease in tr…
Options picks · AVXL
ITM + OTM ideas from the latest scanLoading…
Congress trades · AVXL
STOCK Act disclosuresLoading…
SEC filings & insiders · AVXL
EDGAR · liveLoading…
Holders · AVXL
Institutions & insider activityLoading…